The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 5, 2011, at the Scandic Star Hotel Lund, Glimmervagen 5 in Lund, Sweden.
Please see the attached notification, which is being published within short in Svenska Dagbladet and Post- och Inrikes Tidningar.
Lund, April 5, 2011
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDex for RA. Please visit www.activebiotech.com (http://www.activebiotech.com) for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 5, 2011, at 8:30 a.m.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE